BEAM
Beam Therapeutics Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
30.11
▲ 1.72 (6.06%)
MARKET · —
Price
Open
28.80
Prev close
28.39
Day high
30.50
Day low
28.61
Volume
2.45M
Market cap
—
P/E (TTM)
—
52W range
16.02 – 38.26
Trailing performance
Returnvs SPY
1W
+11.25%
+12.6%
1M
+14.86%
+11.1%
3M
+7.55%
+4.5%
6M
+7.87%
-3.2%
YTD
+7.36%
-4.9%
1Y
+85.31%
+65.3%
3Y
+28.22%
-45.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
27.50
+9.49% from price
SMA 20
27.02
+10.13% from price
SMA 50
29.90
-0.47% from price
SMA 100
29.63
+1.62% from price
SMA 200
28.16
+5.69% from price
EMA 12
27.78
+8.39% from price
EMA 26
28.00
+7.55% from price
EMA 50
28.72
+4.83% from price
RSI (14)
58.0
Neutral
MACD (12,26,9)
-0.22
Hist 0.49
ATR (14)
1.48
4.98% of price
Realised vol 30D
59.7%
Annualised
Bollinger upper
29.28
20, 2σ
Bollinger lower
24.77
20, 2σ
50 / 200 cross
Golden
29.90 vs 28.16
Trend bias
Above 200
+5.69%
Risk profile
Beta vs SPY
2.11
More volatile than market
Correlation to SPY
0.36
Loosely linked
Realised vol 30D
59.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-38.2%
Peak to trough
Max drawdown 5Y
-87.3%
Peak to trough
ATR 14
1.48
4.98% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 16d ago
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Zacks · 17d ago
BofA Adjusts Price Target on Beam Therapeutics to $43 From $47
MT Newswires · 17d ago
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 18d ago
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire · 18d ago
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 23d ago
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Barrons.com · 23d ago
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
GlobeNewswire · 30d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.